Table 3. Adverse events at least... | American Society of Hematology

Table 3.

Adverse events at least possibly related to pembrolizumab

Event	Patients with event, n (%)
Event	All grades, n (%)	Grade 1, n (%)	Grade 2, n (%)	Grade 3, n (%)	Grade 4, n (%)	Grade 5, n (%)
Cytokine release syndrome	1 (8)	0	1 (8)	0	0	0
Infusion-related reaction	1 (8)	0	1 (8)	0	0	0
Fever	3 (25)	1 (8)	2 (17)	0	0	0
Fatigue	1 (8)	1 (8)	0	0	0	0
Dehydration	1 (8)	0	1 (8)	0	0	0
Diarrhea	1 (8)	1 (8)	0	0	0	0
Nausea	1 (8)	0	1 (8)	0	0	0
Hematuria	1 (8)	1 (8)	0	0	0	0
Anemia	1 (8)	0	1 (8)	0	0	0
Lymphocyte count decreased	2 (17)	1 (8)	0	1 (8)	0	0
Neutropenia	4 (33)	1 (8)	0	0	3 (25)	0
Thrombocytopenia	1 (8)	1 (8)	0	0	0	0
Alkaline phosphatase elevated	1 (8)	0	1 (8)	0	0	0
ALT elevated	2 (17)	2 (17)	0	0	0	0
AST elevated	2 (17)	1 (8)	1 (8)	0	0	0
Hyperbilirubinemia	1 (8)	0	0	1 (8)	0	0
Hypocalcemia	1 (8)	1 (8)	0	0	0	0
Synovitis	1 (8)	1 (8)	0	0	0	0
Pleural effusion	1 (8)	1 (8)	0	0	0	0

Event	Patients with event, n (%)
Event	All grades, n (%)	Grade 1, n (%)	Grade 2, n (%)	Grade 3, n (%)	Grade 4, n (%)	Grade 5, n (%)
Cytokine release syndrome	1 (8)	0	1 (8)	0	0	0
Infusion-related reaction	1 (8)	0	1 (8)	0	0	0
Fever	3 (25)	1 (8)	2 (17)	0	0	0
Fatigue	1 (8)	1 (8)	0	0	0	0
Dehydration	1 (8)	0	1 (8)	0	0	0
Diarrhea	1 (8)	1 (8)	0	0	0	0
Nausea	1 (8)	0	1 (8)	0	0	0
Hematuria	1 (8)	1 (8)	0	0	0	0
Anemia	1 (8)	0	1 (8)	0	0	0
Lymphocyte count decreased	2 (17)	1 (8)	0	1 (8)	0	0
Neutropenia	4 (33)	1 (8)	0	0	3 (25)	0
Thrombocytopenia	1 (8)	1 (8)	0	0	0	0
Alkaline phosphatase elevated	1 (8)	0	1 (8)	0	0	0
ALT elevated	2 (17)	2 (17)	0	0	0	0
AST elevated	2 (17)	1 (8)	1 (8)	0	0	0
Hyperbilirubinemia	1 (8)	0	0	1 (8)	0	0
Hypocalcemia	1 (8)	1 (8)	0	0	0	0
Synovitis	1 (8)	1 (8)	0	0	0	0
Pleural effusion	1 (8)	1 (8)	0	0	0	0